Research programme: calpain inhibitors - Teva Pharmaceutical Industries

Drug Profile

Research programme: calpain inhibitors - Teva Pharmaceutical Industries

Latest Information Update: 27 Oct 2011

Price : $50

At a glance

  • Originator Cephalon
  • Class
  • Mechanism of Action Calpain inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Stroke

Most Recent Events

  • 26 Mar 2007 Discontinued - Preclinical for Stroke in USA (unspecified route)
  • 15 Dec 2003 No development reported - Preclinical for Stroke in USA (unspecified route)
  • 04 Jun 2002 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top